Life Sciences Archive » January, 2015

Life Sciences - January, 2015

323 articles

• Bayer Settles Workers' $100M Sex Discrimination Suit
• CVS Accuses Former Director Of Stealing Trade Secrets
• FTC Orders Divestitures In $4B Sun-Ranbaxy Pharma Merger
• Latham's Shake Shack IPO Grabs Spotlight Amid Busy Week
• Philips Gets Nod To Pursue Infringement Claims Against Zoll
• Some Insurers Use Drug Prices To Discriminate, Report Says
• Risperdal Judge Warns J&J Over Introducing FDA Docs
• Medicis Can't Duck Acne Med Suit Under Intermediary Doctrine
• Abbott Labs Escapes Class Cert. Bid By Ensure Drinkers
• SEC Dismisses Herbalife Insider Trading Case
• FDA Accused Of Helping J&J Cover Up Risperdal Data
• Spark Therapeutics Soars After Raising $161M In Upsized IPO
• Valeant Eyes $296M Prostate Drug In 1st Post-Allergan Play
• Thoughts On Consolidating Federal And State Antitrust Cases
• A General Counsel's Top 10 Tips On Calif. Wage-And-Hour Law
• FTC's Provigil Pay-For-Delay Suit Passes Actavis Test: Judge
• Tylenol Liver-Damage MDL Bellwether Gets June Trial Date
• J&J Tried To Obscure Risperdal Risks, Ex-FDA Chief Says
• Brown Rudnick Gets Partial Win In Malpractice Fight
• Immunomedics Sidesteps Securities Fraud Suit
• Quest Diagnostics Accused Of Building Calif. Monopoly
• VC-Backed Flex Pharma Stumbles After Pricing Upsized IPO
• GSK's Ebola Vaccine Shows Promise In First Trial
• Chinese Law Key To Vitamin Antitrust Case, 2nd Circ. Hears
• False DaVita Testimony Jeopardizing Privilege In FCA Suit
• Gibson Dunn Nabs Ex-King & Spalding FDA Regulatory Partner
• January Brings Clarity To Some Of 2014's Buzziest M&A Moves
• Omeros Looks To Raise $80M In Follow-On Offering
• Nixon Peabody, Mintz Levin Using Barred Defense, Court Told
• Expert Testimony Falls Short In Fixodent MDL, Judge Says
• Key Questions When Selecting E-Discovery Vendors
• 2nd Circ. To Weigh Chinese Gov't Role In Vitamin C Appeal
• Cancer Biotech Kolltan Pharmaceuticals Pulls $86M IPO
• 6th Circ. Yanks Payments To 2nd-Priority Dow Implant Victims
• EU OKs $23B Novartis, GlaxoSmithKline 3-Part Deal
• FDA Boosts Defibrillator Oversight After Device Failures
• Ex-FDA Chief Says J&J Knew Adolescent Risperdal Risks
• Fraud Suits Targeting Sanofi Over MS Drug Prospects Tossed
• HHS Asks DC Court To Nix PhRMA's 340B Orphan Drug Suit
• Atara Joins Flood Of Life Science Cos. Tapping Market
• Product Liability Trials To Watch In 2015
• Medtronic Unit Gets Another Bosch Telehealth Patent Nixed
• Hagens Berman Didn't Verify Thalidomide Claim, Court Told
• Growth Hormone Biotech Ascendis Raises $108M In IPO
• Kirkland Steers Traditional Chinese Med. Co. In $1.34B Buy
• VC-Backed Spark Therapeutics Boosts IPO Target To $157M
• Reflections On The Remarkable Rise Of Orphan Drugs
• Takeaways From Indian Court Ruling In Symed V. Glenmark
• Effexor Plaintiffs Want To Drop 40% Of Suits From MDL
• And Now A Word From The Panel: 2014 JPML Practice Trends
• Sandoz, Mylan Lose Bid For Speedy Copaxone Remand
• House GOP Unveils Sweeping FDA Overhaul
• J&J, Bristol-Myers Get AWP Claims Nixed In Pa. Court
• Investment Firms Sue Merck Over Misleading Vioxx Claims
• Wis. AG, Novartis Settle Wholesale Drug Pricing Dispute
• McDermott Snags Health IT Pro From Mintz Levin
• Boehringer, Amneal Strike Deal To End Aggrenox Patent Row
• Silicon Valley Bank Parent Prices $350M In Senior Notes
• Pfizer Strikes $400M Deal To End Shareholder Suit
• Forest Labs Blasts Bid To Expand Class in Sex Bias Suit
• House Panel Takes Up DEA Drug Approval, Enforcement Bills
• Myriad Settles Breast Cancer Test Patent Suit With Ambry
• Zosano's $50M IPO Kicks Off 9 Expected Life Science Debuts
• FDA Policy On Wellness Products Is Healthy For Industry
• New Medical Marijuana Plan Sparked In Pa.
• Ranbaxy, AstraZeneca Say Pay-For-Delay Deal Is Not Unlawful
• IP Firm Can't Dodge Med. Device Co.'s Malpractice Claims
• Muscle Milk Nutrition Claims Are Lean On Facts, Class Says
• An Early Test Of Antitrust Ramifications Of FDA's REMS
• Big Firms Got A Break From Securities Class Actions In 2014
• SAC Victims' Fund OK'd In $602M Insider Trading Deal
• FDA Backs Teva's Generic Nexium In Blow To Ranbaxy
• Tussle Erupts At High Court Over Teva Copaxone Suit Remand
• AIA Reviews Are A Game-Changer For Pharma, Survey Shows
• J&J Didn't Warn Of Risperdal Breast-Growth Risk, Jury Told
• Justices Remand 3 Cases Following Claim Construction Ruling
• Sandoz Says Amgen Biosimilar Claims Conflict With ACA
• FDA Taps Duke Research Expert To Head Drug, Tobacco Unit
• FDA Approves 1st-Ever Glucose Monitoring Apps
• Expert In Zoloft MDL Was Properly Excluded, Judge Says
• McDonnell Remains Free Pending 4th Circ. Appeal
• King & Spalding Lures 2 Enviro Partners From Kirkland & Ellis
• Myriad Settles Cancer Test Patent Suits With 3 Defendants
• The Future Of UK Pharmaceutical Best Practices
• BMS Asks High Court To Review Hepatitis Drug Patent Row
• With Irish Court's OK, Medtronic Completes $50B Inversion
• Insurer Off Hook For Suits Claiming Supplement Is Like Meth
• Nexium Ruling Offers Road Map For Pay-For-Delay Classes
• Human Egg Donors Near Cert. Of Antitrust Class In Pay Row
• Effexor Buyers To Join 3rd Circ. Appeal Against Wyeth, Teva
• J&J's Risperdal Caused Boy's Breast Growth, Philly Jury Told
• 2 IPOs Raise $375M As Slew Of Others Prepare Debuts
• Stanford Says PTAB Wrong To Nix Prenatal Testing Patent
• Economists, Docs Back Actavis In Namenda Injunction Row
• 9th Circ. Flips Kimberly-Clark Unit's Pain Pump Win
• Generic Drug Cos. Face Failure-To-Warn Claims In Calif.
• 3 More Biotech Cos. Set IPO Terms Amid Flurry Of Activity
• J&J Fraud Claims Fall Flat In Mesh MDL, Plaintiffs Attys Say
• Medtronic Can Withhold Trade Secrets At $561M IRS Trial
• Top 5 Developments In Reverse Payments Over The Last Year
• Mylan Wrings Another $13.7M From GSK In Generic Paxil Row
• Fed. Circ. Told Only It Can Hear Patent Interference Appeal
• 1st Circ. OKs Class Cert. In Nexium Pay-For-Delay Suit
• A Data Security Checklist For Companies Hiring Law Firms
• Astellas Strikes $98M Deal In Prograf Antitrust MDL
• High Court ACA Subsidy Case Could Unravel Health Reform
• Novartis Wins FDA Approval For Novel Psoriasis Drug
• Venture-Backed Inotek Targets $100M In IPO, Note Offering
• FTC Stays Tough On Health Software, Even As FDA Eases Up
• Pot Dispenser Co. Faces Suit Over Fraudulent Finances
• Wal-Mart Can't Duck False Ad Suit Over Heart Supplement
• LabCorp Launches $2.9B Notes Offering To Back Covance Deal
• Plaintiffs Pick Test Case In Zimmer Knee Implant MDL
• Judge Selects 6 Bellwether Contenders In Vaginal Sling MDL
• Minority Powerbrokers Q&A: Dykema's Sherrie Farrell
• Medtronic Deal Highlights FTC Focus On Future Competition
• New Considerations For File Wrapper Estoppel
• IntenseX Falsely Touted As Sex-Enhancing Pill, Suit Says
• J&J Makes Final Trial Push Over Failed $21B Guidant Merger
• Pfizer Schemed To Block Celebrex Generics, New Suit Says
• Refusal To Nix Mylan IP Suit Causes Split Among Del. Judges
• What Legal Departments Can Expect If Buying Into E-Billing
• Pfizer Unit Can't Force Actavis To Alter Generic Drug Label
• Patent-Eligibility Guidelines Too Restrictive, USPTO Told
• FDA's Eased Oversight Is Good Omen For Health IT
• Life Sciences Cos. Eye $1.5B Through Follow-On Offerings
• In Wake Of Merger Vote, Covidien Loses Lawyer To Hologic
• Cos. Say Rival Got Confidential Docs In Diabetes Drug MDL
• High Court Urged To Review Damages Ruling In $5M IP Row
• Minority Powerbrokers Q&A: Baker Botts' Alex Bourelly
• Jury's $2M Verdict In Bard Mesh Bellwether Stands
• How High Court Teva Ruling Will Affect Patent Litigants
• Confusion Persists Over Medical Marijuana Enforcement
• Philly Xarelto Suits Combined Into Mass Tort Program
• FCPA Trends From The Last 6 Months
• Life Sciences Group Of The Year: White & Case
• Astellas Nears Settlement In Prograf Antitrust Row
• High Court Snub To Teva Labeling Case Puts Focus On FDA
• High Court Claim Construction Ruling Set To Spur New Fights
• Judge Stands By FDA's Approval Of Gout Drug
• La. Wins Remand Of Fresenius Suit In Dialysis Drug MDL
• Biz Profs Back Actavis In NY AG Antitrust Injunction Fight
• Actos Was Pa. Man's Biggest Bladder Cancer Risk, Expert Says
• Lawyers Weigh In On High Court Claim Construction Ruling
• High Court Lets Teva Drug Labeling Suit Go Ahead
• Deals Rumor Mill: Hillhouse, Orbitz, Salix Pharmaceuticals
• Attys Spar Over Protections For Watchdog Employees In NJ
• Spark Eyes $108M IPO As Slew Of Life Science Cos. Set Terms
• J&J Unit Settles 111 Suits In ObTape Vaginal Sling MDL
• 3 In-House Management Strategies For 2015
• Arthrex Can't Nix Jury's $29M Patent Verdict In Fed. Circ.
• Supreme Court Won't Hear Appeal Over Ohio Landfill Cleanup
• FTC Finalizes Novartis Nicotine Patch Divestiture Deal
• Suboxone Buyers Urge Court Against Reckitt's Recon Bid
• Judge Doubts Jurisdiction In Mouthwash Suit
• Europe Plunks $115M Into J&J Ebola Vaccine Research
• FCA Fines Reckitt Benckiser Over Exec Trading Disclosures
• High Court Orders Claim Construction Deference
• Top 5 Software-Patenting Issues For Life Science Companies
• Boston Scientific, Plaintiffs Spar On Mesh MDL Experts
• Medtronic Unit Gets Bosch Telehealth Patents Nixed By PTAB
• 5th Circ. Won't Give Jailed Fen-Phen Atty New Hearing
• Drug Developer Lays Out Terms For $87M IPO
• Market Rumors: Azul, Taikang Life, GlaxoSmithKline
• FDA Unveils New Low-Risk Medical Device Guidance
• Life Sciences Group Of The Year: Sullivan & Cromwell
• Taxation With Representation: Davis Polk, Cravath, Alston
• Promega, Life Tech Both Urge Fed. Circ. To Review IP Ruling
• Baker Botts Reps Depomed In $1B J&J Unit Drug Rights Deal
• Effexor Buyers To Take Antitrust Suit To 3rd Circ.
• Roche Caps $2B Week With French Drug Co. Buy
• De Novo Review Of Claim Construction: 5 Pros, 5 Cons
• Novartis Should Win In Aredia Osteonecrosis Suit: Judge
• PharmAthene Gets $195M In Final Judgment On SIGA Fight
• Life Sciences Group Of the Year: Skadden
• FDA Says Dozens Given Nonsterile Simulated Saline
• Fed. Circ. Says IP Malpractice Suit Belongs In State Court
• Firms Take $72M Bayer MDL Fee-Shifting Fight To High Court
• Expert Links Actos To Bladder Cancer In Philly Trial
• FDA Downplays 2014 Lull In Drug Promo Discipline
• Valeant Launches $1B Private Senior Notes Offering
• Fight Over Jurisdiction Revived In Case Of Facebook Post
• Becton Wins Partial Stay Of Injunction In $340M Antitrust Suit
• CMS Vows Less Mess In New Round Of Open Payments
• Wyeth, Alaven Dodge Generic Reglan Suit
• Darwin Must Pay $8.7M To Cover Millennium False-Ad Suits
• Pharmacy Tells Texas Justices It's A Health Care Provider
• 23andMe Clients Can't Arbitrate False Ad Claims As Class
• Life Sciences Group Of The Year: Morgan Lewis
• Actos Caused Consumer's Bladder Cancer, Philly Jury Hears
• CORRECTED: PTAB Nixes Biz Method Review Of Jazz Drug Patents
• Deals Rumor Mill: Boehringer, TI Automotive, TransDigm
• Women Asked To Lie To Join Pelvic Mesh MDL, J&J Claims
• FDA Clears First-Ever Anti-Obesity 'Pacemaker'
• Trustee Objects To Device Maker's Supply Agreement
• Hatch Introduces Senate Bill To Repeal Medical Device Tax
• Minority Powerbrokers Q&A: Sterne Kessler's Dr. Longsworth
• Bellerophon Eyes $69M IPO After Spinoff From Ikaria
• Roka Slapped With Putative Class Action Over Deceptive IPO
• 2014 Health Care Enforcement Year In Review: Part 2
• 5 Important Drug And Medical Device Developments In 2014
• NY AG Stops Harm To Alzheimer's Patients — For Now
• Pfizer Dodges Asbestos Suit Over Ex-Unit's Product
• Middle Market IPOs Soar Despite Drop In Capital Raised
• Fed. Circ. Ruling Shows Appetite For Revisiting Willfulness
• Life Sciences Group Of The Year: Latham & Watkins
• Utah Bill Would Give Dying Access To Experimental Drugs
• Deals Rumor Mill: CIMB Group, Xstrata, TowerBrook
• Bard Can't Delay Upcoming Mesh Trial Over Judge's Remarks
• AstraZeneca Urges Fed. Circ. To Halt Mylan's Jurisdiction Fight
• Eisai Pushes 3rd Circ. To Revive Sanofi Antitrust Suit
• Cold Medicine Co. Can't Escape False Ad Suit
• CVS Balks At Discovery Docs In Novartis Kickbacks Suit
• Ex-Virginia Gov. McDonnell Denied Appeal Bond
• BMS, Citi, Others On Hook For $92M NJ Superfund Settlement
• Fed. Circ. Says Gore Must Pay $1B In Patent Saga
• Judge Urged To Delay Sanctions In Dental Implant IP Suit
• Stryker TCPA Class Action Sent Toward Trial
• 2014 Health Care Enforcement Year In Review: Part 1
• A Survey Of Patent Invalidations Since Alice
• High Court KBR Fight Could Lead To Endless FCA Litigation
• Actavis Urges 2nd Circ. To Toss 'Dangerous' Antitrust Order
• Hospira Joins Biosimilars Race With FDA Application
• MLB Ordered To Disclose Witness Payments In Doping Suit
• High Court Nixes Allergan Appeal Of Generic Latisse IP Case
• Supreme Court Won't Review Disbarment Of Jailed Texas Atty
• FDA Forges Ahead On Reform Of Drug Ads' Risk Disclosures
• Repeal Of Medical Device Tax Could Imperil Other ACA Taxes
• $2B Steris Inversion Could Be Delayed By Deeper FTC Probe
• Life Sciences Group Of The Year: Kaye Scholer
• Amerisource To Boost Animal Health Biz With $2.5B MWI Buy
• Roche Nabs $1B Majority In Cancer Research Co.
• Shire Inks $5.2B Deal For US Biotech NPS Pharma
• Pharmacies Face Greater Med Mal Risk In Texas Case
• Generics Makers Lose Bid To Nix Vimpat Patent In AIA Review
• Fed. Circ. Axes Merck Unit's En Banc Bid In Patent Dispute
• Life Sciences Group Of The Year: Covington & Burling
• Jones Day Seeks Oral Args Over Sanctions In Abbott Row
• Mylan Asks PTAB To Reconsider Denial Of Viread Reviews
• Ballot Initiative Could Give Ohio Voters Crack At Pot Law
• Canadian Drug Imports Could Save US Buyers Millions: Sens.
• Swedish Antitrust Officials Clear $767M ICA-Apotek Merger
• Maligned Speech-Supplement Producer Settles With FTC
• Daiichi Sankyo Pays $39M To Settle FCA Suit With Feds
• Law Schools Are (Finally) Teaching 'The Biz' Of Lawyering
• Fed. Circ. Skirts Biologics Law In Sandoz Ruling
• CytRx Board Must Face Claims It 'Spring-Loaded' Options
• Plaintiffs Can Introduce New Expert In Zoloft MDL, Judge Says
• Zurich Denied Quick Appeal In Eisai Coverage Fight
• Sens. Float Bill To Let Medicare Negotiate Drug Prices
• 5 Lessons From FDA's First Biosimilar Review
• 'Garbage' Counterclaims Claim Nixed In Androgel IP Case
• Allergan Can't Tighten Time Frame For Cancer Risk Claims
• Fed. Circ. Affirms PTAB Ruling On Hearing Device Patent
• Alder BioPharma Prices Offering At $177M
• Walgreen Escapes False Ad Suit Over Homeopathic Ear Meds
• Mylan, Abbott Offer EU Antitrust Fixes On $5.3B Inversion
• GSK, Novartis Offer EU Antitrust Fixes On $23B Deals
• Biotech Co. Xencor Sets Stage For $150M Follow-On Offering
• Judge Urged to Kill AstraZeneca, Ranbaxy Pay-For-Delay Deal
• Gilead Wins Dismissal Of Defective Drug Fraud Suit
• FTC Sues Children's Supplement Maker For False Claims
• 6 Industries Primed For M&A This Year
• Calif. Fixes Timing Problem For Post-Trial Motions
• GSK Stuck With Experts From First Abbott HIV Drug Trial
• J&J Unit Dodges Final Claims In Ortho Evra MDL
• Kean University Loses Fight Over Rights To Merck Parcel
• Vitamin Shoppe Supplement Not Organic, Suit Says
• 2nd Circuit Rules NY Can Keep Mandatory Vaccine Law
• Amgen Tries To Force Sandoz Biosimilar Disclosures
• CVS Gets FCA Claims Of Novartis Kickbacks Trimmed
• Web Postings Removal Ordered In NuScience IP Row
• Sandoz Biosimilar Clears FDA Panel In Milestone Vote
• Bard Fights To Delay Mesh Trial After Judge Urges Settling
• Kan. OKs $231M In Bonds For DHS Bio-Defense Facility
• Market Rumors: Trainline.com, Genkyotex, Dick's
• PharmAthene Gets $113M Lost Profits Award In SIGA Spat
• Mylan Asks Fed. Circ. To Mull Hatch-Waxman Jurisdiction
• House GOP Begins Assault On ACA's Medical Device Tax
• Printing Co. Exec Cops To $7M False Billing Scheme
• US Seizes $18M From NECC Owners Charged In Outbreak
• Secrets To In-House Cost Control
• 2nd Circ. OKs Quick Actavis Appeal In Namenda Antitrust Suit
• Liberty Medical Creditors Push To Sue Brass Over Pay
• Insurer Shakes BioChemic's Suit Over SEC Subpoena Claim
• Endo TCPA Suit Paused While FCC Mulls Solicited Fax Regs
• Ocular Disease-Focused Biotechs Eye Follow-On Offerings
• Alder BioPharma Eyes $124M Offering To Fund Development
• LifeNet Argues LifeCell Can't Undo $35M Patent Win
• Ex-Va. Gov. McDonnell Gets 2 Years For Corruption
• Arthrex Asks Fed. Circ. To Nix Jury's $29M Patent Verdict
• Investors Cheer $48B Medtronic Deal, Biggest Inversion Yet
• Overbroad Patent Claims May Be Challenged Earlier
• Calif. County Drug Cleanup Law Is Illegal, High Court Told
• Law360's Pay-For-Delay Cheat Sheet For 2015
• Actavis Accuses NY AG Of Trying To Slow Injunction Appeal
• Miss. AG Wins Remand Of Fresenius Suit In Dialysis Drug MDL
• Deals Rumor Mill: NPS, Morgan Stanley, Club Med
• Pfizer Nabs Majority Stake In Swiss Vaccine Manufacturer
• FDA Warns Novacap About 'Serious' Flaws At Chinese Facility
• Brazilian Officials Seek Fines In Alleged HIV Drug Cartel
• Sandoz Biosimilar Wins Support From FDA Staff
• AxelaCare Moves Into Southeast With Florida Health Co. Buy
• Bayer Asks 8th Circ. To Revisit FCA Retaliation Award
• $48B Medtronic Inversion Faces Blowback As It Heads To Vote
• Device Maker HEI Turns To Ch. 11 For Liquidation Sales
• Shifting Industry Options For Paying Physician Educators
• 12 Building Blocks Of A Digital Law Library
• Ex-Stiefel Exec. Can't Toll Stock Claims, 11th Circ. Rules
• 11th Circ. OKs Remand Of Lilly Rep's Suit To Fla. Court
• Skin Grafting Co. Sues Rival Over Pulled VA Contracts
• Aethlon Wins FDA Approval For Ebola Treatment Trials
• Life Sciences Cases To Watch In 2015
• Attys Accused Of Not Repaying $5.9M Loans For Drug Torts
• NJ Court Scraps Copayment Hikes For Public Worker Retirees
• Nexium Buyers Seek New Trial In Pay-For-Delay Case
• NY AG Says Actavis Can't Suspend Antitrust Injunction
• Life Sciences Legislation And Regulation To Watch In 2015
• GlaxoSmithKline Atty Suspended For 6 Months For M&A Work
• Jones Day Atty's Sanctions Should Be Upheld, 8th Circ. Told
• USPTO Guidelines Bring More Clarity To Patent Eligibility
• What To Expect In Criminal Antitrust This Year
• 2015: Judiciary, Lawyers And Law Schools At The Precipice